HAZAF yields 6.91% · PFE yields 6.13%● Live data
📍 HAZAF pulled ahead of the other in Year 1
Combined, HAZAF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HAZAF + PFE for your $10,000?
Hazama Ando Corporation engages in the construction and construction-related business in Japan and internationally. The company offers civil engineering and building construction services, including surveys, measurements, planning, designing, executing, supervising, technical guidance contract, commissioning, and consulting services. Its projects include offices, production and distribution facilities, medical and welfare facilities, educational and research facilities, cultural and sports facilities, commercial and leisure facilities, traditional facilities, housing complexes, and other buildings; and dams, water/sewer systems, tunnels, roads and land reclamation, bridges, airports, and other public works, as well as renewal, urban civil engineering, civil engineering structure, offshore engineering, and other projects. The company also provides real estate transaction services; and owns and uses real properties and securities. In addition, it undertakes soil survey and purification works, such as the collection, handling, and disposal of waste, as well as related consulting services; and offers planning, designing, and consulting services related to area and urban development, environmental improvements, etc. Further, the company is involved in power generation; and electricity, thermal, and other energy supply activities. Additionally, it sells construction materials, machinery, and appliances; develops, licenses, and sells software; and provides building maintenance and security services. The company was formerly known as Hazama Corporation and changed its name to Hazama Ando Corporation in April 2013. Hazama Ando Corporation was founded in 1873 and is headquartered in Tokyo, Japan.
Full HAZAF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.